{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:17:02Z","timestamp":1773717422799,"version":"3.50.1"},"reference-count":82,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T00:00:00Z","timestamp":1659830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Craniopharyngiomas (CPs) are rare tumors of the skull base, developing near the pituitary gland and hypothalamus and responsible for severe hormonal deficiencies and an overall increase in mortality rate. While surgery and radiotherapy represent the recommended first-line therapies for CPs, a new paradigm for treatment is currently emerging, as a consequence of accumulated knowledge concerning the molecular mechanisms involved in tumor growth, paving the way for anticipated use of targeted therapies. Significant clinical and basic research conducted in the field of CPs will undoubtedly constitute a real step forward for a better understanding of the behavior of these tumors and prevent associated complications. In this review, our aim is to summarize the multiple steps in the management of CPs in adults and emphasize the most recent studies that will contribute to advancing the diagnostic and therapeutic algorithms.<\/jats:p>","DOI":"10.3390\/cancers14153831","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T21:03:50Z","timestamp":1659906230000},"page":"3831","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Challenging Management of Craniopharyngiomas in Adults: Time for a Reappraisal?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-0030","authenticated-orcid":false,"given":"Thomas","family":"Cuny","sequence":"first","affiliation":[{"name":"Aix Marseille University, MMG, INSERM U1251, MAEMARA Institute, Department of Endocrinology, CRMR HYPO, 13385 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital of Erlangen, 91052 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6725-5006","authenticated-orcid":false,"given":"Henry","family":"Dufour","sequence":"additional","affiliation":[{"name":"Aix Marseille University, MMG, INSERM U1251, MAEMARA Institute, Department of Neurosurgery, CRMR HYPO, 13385 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":false,"given":"Ashley","family":"Grossman","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, Barts and the London School of Medicine, London OX1 2JD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Gatta-Cherifi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CHU of Bordeaux, 33000 Bordeaux, France"},{"name":"Neurocentre Magendie, University of Bordeaux, 33600 Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[{"name":"Skull Base and Pituitary Neurosurgical Department, Reference Centre for Rare Pituitary Diseases HYPO, \u2018Groupement Hospitalier Est\u2019 Hospices Civils de Lyon, 69500 Bron, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"INSERM U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon, 69000 Lyon, France"},{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u2018Groupement Hospitalier Est\u2019 Hospices Civils de Lyon, 69500 Bron, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Vasiljevic","sequence":"additional","affiliation":[{"name":"East Center of Pathology and Neuropathology, \u201cGroupement Hospitalier Est\u201d, Hospices Civils de Lyon, 69500 Bron, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Frederic","family":"Castinetti","sequence":"additional","affiliation":[{"name":"Aix Marseille University, MMG, INSERM U1251, MAEMARA Institute, Department of Endocrinology, CRMR HYPO, 13385 Marseille, France"},{"name":"Department of Endocrinology, La Conception Hospital, 147 Boulevard Baille, CEDEX 05, 13385 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"Merchant","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11102-021-01127-6","article-title":"Descriptive epidemiology of craniopharyngiomas in the United States","volume":"24","author":"Momin","year":"2021","journal-title":"Pituitary"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2156","DOI":"10.1210\/clinem\/dgab893","article-title":"High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort","volume":"107","author":"Kariyawasam","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.wneu.2019.11.111","article-title":"Malignant Craniopharyngioma: A Report of Seven Cases and Review of the Literature","volume":"135","author":"Wang","year":"2020","journal-title":"World Neurosurg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1227\/NEU.0000000000000380","article-title":"Malignant transformation in craniopharyngiomas","volume":"75","author":"Sofela","year":"2014","journal-title":"Neurosurgery"},{"key":"ref_7","first-page":"123","article-title":"Metastatic papillary craniopharyngioma: Case study and study of tumor angiogenesis","volume":"4","author":"Elmaci","year":"2002","journal-title":"Neuro-Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","article-title":"Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles","volume":"4","author":"Sill","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EJE-17-0044","article-title":"Very long-Term sequelae of craniopharyngioma","volume":"176","author":"Wijnen","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1159\/000509616","article-title":"Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma","volume":"110","author":"Erfurth","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3389\/fonc.2020.01014","article-title":"Social Cognition in Patients with Hypothalamic-Pituitary Tumors","volume":"10","author":"Mehren","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrendo.2013.125","article-title":"Paediatrics: Surgical strategy and quality of life in craniopharyngioma","volume":"9","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2265.2004.02196.x","article-title":"High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma","volume":"62","author":"Pereira","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1210\/er.2013-1115","article-title":"Craniopharyngioma","volume":"35","year":"2014","journal-title":"Endocr. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3390\/curroncol29030118","article-title":"The Role of Surgical Approaches in the Multi-Modal Management of Adult Craniopharyngiomas","volume":"29","author":"Hong","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41366-018-0185-z","article-title":"Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity","volume":"43","author":"Fjalldal","year":"2019","journal-title":"Int. J. Obes."},{"key":"ref_19","first-page":"2734","article-title":"Obesity in childhood craniopharyngioma: Relation to post-operative hypothalamic damage shown by magnetic resonance imaging","volume":"81","author":"Grant","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1016\/j.wneu.2019.07.217","article-title":"Ommaya Reservoir System for the Treatment of Cystic Craniopharyngiomas: Surgical Results in a Series of 11 Adult Patients and Review of the Literature","volume":"132","author":"Frio","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000493061","article-title":"The Role of Leksell Radiosurgery in the Management of Craniopharyngiomas","volume":"34","author":"Niranjan","year":"2019","journal-title":"Prog. Neurol. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1159\/000506902","article-title":"Radiotherapy of Parasellar Tumours","volume":"110","author":"Albano","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.21037\/cco.2016.07.05","article-title":"Proton therapy for tumors of the base of the skull","volume":"5","author":"Noel","year":"2016","journal-title":"Chin. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrendo.2010.4","article-title":"Role of stereotactic radiosurgery in the management of pituitary adenomas","volume":"6","author":"Castinetti","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/neuonc\/nox056","article-title":"Intracystic interferon-alpha in pediatric craniopharyngioma patients: An international multicenter assessment on behalf of SIOPE and ISPN","volume":"19","author":"Kilday","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_26","first-page":"CD008890","article-title":"Intracystic bleomycin for cystic craniopharyngiomas in children","volume":"7","author":"Zhang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: A consensus statement","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jocn.2012.04.014","article-title":"Craniopharyngioma cell growth is promoted by growth hormone (GH) and is inhibited by tamoxifen: Involvement of growth hormone receptor (GHR) and IGF-1 receptor (IGF-1R)","volume":"20","author":"Li","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1530\/EJE-12-0077","article-title":"Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up","volume":"166","author":"Olsson","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-18-0505","article-title":"Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo)","volume":"179","author":"Boekhoff","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/clinem\/dgaa089","article-title":"Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence","volume":"105","author":"Losa","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","first-page":"e4734","article-title":"Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study","volume":"106","author":"Wolf","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","article-title":"Hypothalamic syndrome","volume":"8","author":"Tauber","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"846880","DOI":"10.3389\/fendo.2022.846880","article-title":"Treatment of Acquired Hypothalamic Obesity: Now and the Future","volume":"13","author":"Dimitri","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1748-717X-9-203","article-title":"Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: Maximal tumor control with minimal side effects","volume":"9","author":"Harrabi","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-015-1885-z","article-title":"A systematic review of cognitive performance in patients with childhood craniopharyngioma","volume":"125","author":"Thiel","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.wneu.2022.05.038","article-title":"Quality of Life in Craniopharyngioma: A Systematic Review","volume":"164","author":"Shi","year":"2022","journal-title":"World Neurosurg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12020-017-1489-9","article-title":"Quality of life and growth after childhood craniopharyngioma: Results of the multinational trial KRANIOPHARYNGEOM 2007","volume":"59","author":"Heinks","year":"2018","journal-title":"Endocrine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/path.1562","article-title":"Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma","volume":"203","author":"Kato","year":"2004","journal-title":"J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/S0002-9440(10)64477-X","article-title":"Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations","volume":"161","author":"Sekine","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-004-5232-z","article-title":"Beta-catenin mutations in craniopharyngiomas and pituitary adenomas","volume":"73","author":"Oikonomou","year":"2005","journal-title":"J. Neurooncol."},{"key":"ref_42","first-page":"126","article-title":"Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma","volume":"76","author":"Goschzik","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/nan.12613","article-title":"CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma","volume":"46","author":"Apps","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1073\/pnas.1101553108","article-title":"Increased Wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans","volume":"108","author":"Andoniadou","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/01.pas.0000213328.64121.12","article-title":"Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and rathke cleft cysts: A clinico-pathologic approach","volume":"30","author":"Hofmann","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-006-0184-3","article-title":"Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas","volume":"113","author":"Buslei","year":"2007","journal-title":"Acta Neuropathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bpa.12501","article-title":"Genetically engineered mouse models of craniopharyngioma: An opportunity for therapy development and understanding of tumor biology","volume":"27","author":"Apps","year":"2017","journal-title":"Brain Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_49","first-page":"2141","article-title":"MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma","volume":"144","author":"Haston","year":"2017","journal-title":"Development"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/EJE-21-1269","article-title":"Telomere length and Wnt\/\u03b2-catenin pathway in adamantinomatous craniopharyngiomas","volume":"187","author":"Mota","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12974-022-02470-6","article-title":"Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of \u03b2-amyloid","volume":"19","author":"Ainiwan","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e000406","DOI":"10.1136\/jitc-2019-000406","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma","volume":"8","author":"Wang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"830793","DOI":"10.3389\/fgene.2022.830793","article-title":"Integrative Analysis of Biomarkers and Mechanisms in Adamantinomatous Craniopharyngioma","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Schreck, K.C., Grossman, S.A., and Pratilas, C.A. (2019). BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers, 11.","DOI":"10.3390\/cancers11091262"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","article-title":"BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma","volume":"127","author":"Larkin","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/neuonc\/not195","article-title":"Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth","volume":"16","author":"Stache","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s11102-019-00983-7","article-title":"Craniopharyngiomas presenting as incidentalomas: Results of KRANIOPHARYNGEOM 2007","volume":"22","author":"Boekhoff","year":"2019","journal-title":"Pituitary"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/02841851960373P275","article-title":"Pre- and postoperative MR imaging of craniopharyngiomas","volume":"37","author":"Hald","year":"1996","journal-title":"Acta Radiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"752119","DOI":"10.3389\/fneur.2021.752119","article-title":"Application of Artificial Intelligence in Diagnosis of Craniopharyngioma","volume":"12","author":"Qin","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3171\/2017.4.JNS163113","article-title":"Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features","volume":"129","author":"Yue","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chen, X., Tong, Y., Shi, Z., Chen, H., Yang, Z., Wang, Y., Chen, L., and Yu, J. (2019). Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach. BMC Neurol., 19.","DOI":"10.1186\/s12883-018-1216-z"},{"key":"ref_64","first-page":"3","article-title":"Pediatric craniopharyngiomas: Classification and treatment according to the degree of hypothalamic involvement","volume":"106","author":"Puget","year":"2007","journal-title":"J. Neurosurg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1016\/j.wneu.2019.06.037","article-title":"Is Gross Total Resection Reasonable in Adults with Craniopharyngiomas with Hypothalamic Involvement?","volume":"129","author":"Apra","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00432-021-03791-4","article-title":"The eagle sign: A new preoperative MRI-based tool for predicting topographic correlation between craniopharyngioma and hypothalamus","volume":"148","author":"Li","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2016.9.FOCUS16304","article-title":"Craniopharyngioma adherence: A comprehensive topographical categorization and outcome-related risk stratification model based on the methodical examination of 500 tumors","volume":"41","author":"Prieto","year":"2016","journal-title":"Neurosurg. Focus"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/neuonc\/noz156","article-title":"The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors","volume":"21","author":"Mattox","year":"2019","journal-title":"Neuro-Oncology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","article-title":"Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid","volume":"4","author":"White","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00701-020-04265-1","article-title":"Surgical management of craniopharyngiomas in adult patients: A systematic review and consensus statement on behalf of the EANS skull base section","volume":"162","author":"Cossu","year":"2020","journal-title":"Acta Neurochir."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-022-03983-z","article-title":"Disease Control after Radiotherapy for Adult Craniopharyngioma: Clinical Outcomes from a Large Single-Institution Series","volume":"157","author":"Rutenberg","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00280-021-04234-0","article-title":"BRAF\/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: A case series","volume":"87","author":"Butt","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful Use of BRAF\/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"vdaa141","DOI":"10.1093\/noajnl\/vdaa141","article-title":"Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"2","author":"Guyon","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.18632\/oncotarget.27203","article-title":"Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: A case report","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: Case report","volume":"130","author":"Himes","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front. Endocrinol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3831\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:05:30Z","timestamp":1760141130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,7]]},"references-count":82,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14153831"],"URL":"https:\/\/doi.org\/10.3390\/cancers14153831","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,7]]}}}